Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Fumihiro Oshita"'
Autor:
Yohei Miyagi, Masahiko Higashiyama, Akira Gochi, Makoto Akaike, Takashi Ishikawa, Takeshi Miura, Nobuhiro Saruki, Etsuro Bando, Hideki Kimura, Fumio Imamura, Masatoshi Moriyama, Ichiro Ikeda, Akihiko Chiba, Fumihiro Oshita, Akira Imaizumi, Hiroshi Yamamoto, Hiroshi Miyano, Katsuhisa Horimoto, Osamu Tochikubo, Toru Mitsushima, Minoru Yamakado, Naoyuki Okamoto
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24143 (2011)
BACKGROUND: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection methods using blood samples. Among metabolites, profiling of plasma free amino acids (PFAAs) is a promising approach because PFAAs link all
Externí odkaz:
https://doaj.org/article/083ba342278b4643b999b9fce8a611e8
Autor:
Mao Matsubayashi1, Fumihiro Oshita2 foshita@ashigarakami-hospital.jp, Natsuki Kawata3, Takafumi Yanagibashi1, Satoshi Tanaka1, Yoshiteru Hao1, Yuichi Kurakami3, Keisuke Iwabuchi3, Yohsuke Kunishi1, Mitsuyasu Ohta3, Yuki Nakamura3, Kohichiro Yoshie3
Publikováno v:
Journal of Experimental Therapeutics & Oncology. 2017, Vol. 12 Issue 2, p143-149. 7p.
Autor:
Fumihiro Oshita1,2 foshita@ashigarakami-hospital.jp, Shuji Murakami1, Tetsuro Kondo1, Haruhiro Saito1, Kouzo Yamada1, Yuko Nakayama3
Publikováno v:
Journal of Experimental Therapeutics & Oncology. 2017, Vol. 12 Issue 1, p17-23. 7p. 4 Charts, 1 Graph.
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:81-87
Cisplatin-based chemotherapy is the standard adjuvant therapy for patients with completely resected stage II or III non-small cell lung cancer (NSCLC). However, the completion rate of four cycles of cisplatin-based chemotherapy is about 50%. This pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf3fe9eddaea83e32800c1199f41b86f
https://doi.org/10.1007/s00280-017-3460-0
https://doi.org/10.1007/s00280-017-3460-0
Autor:
Takashi Seto, Tomohide Tamura, Naoyuki Nogami, Yuichiro Ohe, Noboru Yamamoto, Masashi Wakabayashi, Koichi Goto, Hiroaki Okamoto, Haruyasu Murakami, Hideyuki Harada, Ikuo Sekine, Hiroshi Tanaka, Satoshi Ishikura, Fumihiro Oshita
Publikováno v:
Lung Cancer. 108:232-237
Objectives The objective of this study was to select, for a phase III trial, the more promising of weekly-dose intensive chemotherapy or amrubicin + cisplatin chemotherapy as subsequent therapy after induction chemoradiotherapy for previously untreat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bf4bb3e4d7c9338e1a06fbb59d929d7
https://doi.org/10.1016/j.lungcan.2017.04.002
https://doi.org/10.1016/j.lungcan.2017.04.002
Publikováno v:
Journal of Experimental Therapeutics & Oncology. 2016, Vol. 11 Issue 3, p189-194. 6p. 3 Charts.
Autor:
Hiroyuki Ito, Teppei Nishii, Tetsuro Kondo, Munetaka Masuda, Shoichi Matsukuma, Yataro Daigo, Tomoyuki Yokose, Kouzo Yamada, Hideyuki Furumoto, Shuji Murakami, Tetsuya Isaka, Fumihiro Oshita, Yohei Miyagi, Haruhiko Nakayama, Haruhiro Saito
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 13:e204-e211
Aim With the advent of the molecular-targeted therapy, rapid progress has been made in the treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). Although surgical complete resection remains the standard and most promising treatment,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c6a2386009184ae173a158abe210b14
https://doi.org/10.1111/ajco.12512
https://doi.org/10.1111/ajco.12512
Autor:
Hiroyuki Ito, Munetaka Masuda, Yasushi Rino, Fumihiro Oshita, Takashi Oshima, Takuya Nagashima, Yayoi Kimura, Haruhiko Nakayama, Akiko Okayama, Hisashi Hirano, Yohei Miyagi, Akihide Ryo
Publikováno v:
Journal of Proteomics. 139:60-66
Lung cancer is generally considered as a highly malignant cancer. A major challenge for the management of lung adenocarcinoma patients is to predict the clinical course of the disease after resection. We analyzed the different levels of phosphorylati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30753e58d72063f7badcab878e8375a7
https://doi.org/10.1016/j.jprot.2016.03.005
https://doi.org/10.1016/j.jprot.2016.03.005
Autor:
Satoshi Tanaka, Ayaka Ono, Yoshiteru Hao, Yoshio Kato, Mao Matsubayashi, Natsuki Kanno, Takafumi Yanagibashi, Fumihiro Oshita, Mitsuyasu Ota, Yuichi Kurakami, Yosuke Kunishi, Koichiro Yoshie, Keisuke Iwabuchi
Publikováno v:
Infectious Diseases. 49:772-774
Sir,After its first identification in 1955 in USA [1], human parechovirus (HPeV) has become recognized as a worldwide cause of diarrhoea in children. A recent report from India in this journal illu...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1792654f5eb6876672edb756f8a6ef21
https://doi.org/10.1080/23744235.2017.1323347
https://doi.org/10.1080/23744235.2017.1323347
Publikováno v:
Journal of experimental therapeuticsoncology. 13(2)
Continuation maintenance therapy with pemetrexed (PEM) and bevacizumab (BEV) following induction therapy with cisplatin (CDDP), PEM, and BEV is beneficial in advanced non-squamous non-small-cell lung cancer (NS-NSCLC), but the survival benefit of add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bca359daa50a31b384a82160bc0f7468
https://pubmed.ncbi.nlm.nih.gov/31881129
https://pubmed.ncbi.nlm.nih.gov/31881129